Skip to main content

Table 1 Baseline characteristics of patients in placebo and silymarin groups

From: A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury

 

Silymarin

Placebo

p-value

(N = 27)

(N = 28)

Male (n, %)

10 (37.0)

12 (42.9)

0.785

Age (years)

56.0 (15, 78)

51.5 (21, 83)

0.721

BMI (kg/m2)

21.1 (14.1, 25.4)

21.0 (15.8, 27.0)

0.773

Dose of Isoniazid (mg/kg)

5.5 (4.0, 9.0)

5.7 (4.5, 7.7)

0.968

Dose of rifampicin (mg/kg)

10.4 (8.0, 14.0)

10.3 (9.0, 14.0)

0.965

Dose of pyrazinamide (mg/kg)

23.1 (18.6, 29.1)

23.8 (17.8, 58.0)

0.282

Dose of ethambutol (mg/kg)

18.5 (13.3, 24.9)

18.5 (12.7, 27.8)

0.859

Liver function tests

 ALT (IU/L)

29 (15, 66)

31 (11, 86)

0.639

 AST (IU/L)

20 (13, 106)

25.5 (14, 56)

0.087

 ALP (IU/L)

85 (37, 449)

89.5 (55, 508)

0.736

 GGT (IU/L)

42 (17, 430)

52.5 (14, 510)

0.443

 TP (g/L)

78.1 (50.5, 91.5)

76.0 (56.1, 99.4)

0.452

 Alb (g/L)

35.7 (23.0, 42.0)

33.0 (16.7, 43.8)

0.639

 TB (mg/dl)

0.5 (0.3, 1.9)

0.6 (0.2, 1.4)

0.285

 DB (mg/dl)

0.2 (0.1, 0.7)

0.3 (0.1, 5.0)

0.015

  1. BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; TP, total protein; Alb, albumin; TB, total bilirubin; DB, direct bilirubin
  2. Categorical variables reported as N (%). Continuous variables reported as median (interquartile range)